[Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis--effect of various antibiotics on extracellular release of verotoxin]
- PMID: 9077070
- DOI: 10.11150/kansenshogakuzasshi1970.71.130
[Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis--effect of various antibiotics on extracellular release of verotoxin]
Abstract
We tested antimicrobial activities of ten oral antibiotics; ampicillin (ABPC), cefdinir (CFDN), cefaclor (CCL), fosfomycin (FOM), norfloxacin (NFLX), nalidixic acid (NA), kanamycin (KM), minocycline (MINO), doxycycline (DOXY), and tetracycline (TC) against eleven enterohemorrhagic Esherichia coli (EHEC) O157 clinical strains. Two strains were resistant to ABPC and TC. Other strains were sensitive to all the ten antibiotics. To investigate the effect of antibiotics on extracellular release of verotoxin (VT), strain EHEC TT10 was grown in 10 ml of LB containing various concentrations of the antibiotics for 2 h. Number of viable cells were counted and the amounts of VT1 and VT2 released in the supernatants were measured with reverse passive latex agglutination (RPLA) using serially diluted sterilized culture supernatants. The amount of VT1 and VT2 was evidently increased with ABPC, CFDN, CCL, and FOM, the inhibitors of cell wall biosynthesis. In the case of quinolons, VT2 was markedly increased, but VT1 was not released to the supernatant. KM killed the bacteria efficiently, but no release of VT1 or VT2 was observed in the supernatant. Tetracyclines (MINO, DOXY, and TC) did not make the bacteria release either VT1 or VT2, but could not kill the bacteria appreciably. These results indicated that the inhibitors of protein synthesis (KM, MINO, DOXY, TC) are the safe antibiotics not causing the release of verotoxin from the cells and thus preventing development of hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpra (TTP), the important sequelae of the enteritis.
Similar articles
-
[In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains].Jpn J Antibiot. 1999 Aug;52(8):541-53. Jpn J Antibiot. 1999. PMID: 10587879 Japanese.
-
[The drug susceptibility pattern of the presumed etiologic agents of infectious enteritis including verotoxin-producing Escherichia coli O-157].Jpn J Antibiot. 1997 Oct;50(10):829-43. Jpn J Antibiot. 1997. PMID: 9412873 Japanese.
-
Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice.J Infect Chemother. 2006 Oct;12(5):251-6. doi: 10.1007/s10156-006-0470-y. Epub 2006 Nov 6. J Infect Chemother. 2006. PMID: 17109087
-
[Characteristics and molecular biology of verotoxin produced by enterohemorrhagic Escherichia coli].Nihon Rinsho. 1997 Mar;55(3):646-50. Nihon Rinsho. 1997. PMID: 9086774 Review. Japanese.
-
[Sporadic cases of hemolytic uremic syndrome and hemorrhagic colitis with serum IgM antibodies to lipopolysaccharides of enterohemorrhagic Escherichia coli O157].Nihon Rinsho. 1997 Mar;55(3):686-92. Nihon Rinsho. 1997. PMID: 9086782 Review. Japanese.
Cited by
-
A novel antimicrobial peptide significantly enhances acid-induced killing of Shiga toxin-producing Escherichia coli O157 and non-O157 serotypes.Microbiology (Reading). 2011 Jun;157(Pt 6):1768-1775. doi: 10.1099/mic.0.047365-0. Epub 2011 Mar 31. Microbiology (Reading). 2011. PMID: 21454368 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical